Tactile Systems Technology, Inc. (TCMD)

Over the past six months, TCMD's stock price has been impacted by several events. The Q3 2025 earnings report showed EPS exceeding forecasts and revenue up 17% year-over-year, leading to stock gains. The company held its Q4 2025 earnings conference call, reporting a 12% increase in total revenue for 2025. The acquisition of Lymphotec aimed to enhance patient surveillance. Updated Medicare criteria provided a tailwind, while a new prior authorization requirement is projected as a potential headwind. As of April 1, 2026, the share price was $25.97, representing an 87.37% increase from April 2, 2025. However, in the past month (leading up to March 31, 2026), the stock decreased by 11.64%. The stock fell by -12.51% in the 10 days leading up to April 10, 2026.

The provided search results do not contain explicit information about the demand seasonality for Tactile Systems Technology, Inc.'s products and services. However, one source indicates that "TCMD Seasonality" displays mean and median monthly returns for TCMD to identify seasonal patterns, suggesting that seasonality in demand or stock performance is a recognized factor for the company.

Tactile Systems Technology, Inc. (TCMD) is a medical technology company focused on developing and providing medical devices for underserved chronic diseases, primarily in the United States. The company's major products include the Flexitouch Plus system, a pneumatic compression device for treating lymphedema and related conditions; the Entre Plus System, another pneumatic compression device for at-home treatment; Nimbl, a pneumatic compression platform for upper extremity lymphedema; Kylee, a mobile application for lymphedema patient support; and AffloVest, a portable high-frequency chest wall oscillation vest for patients with retained pulmonary secretions.

Tactile Systems Technology, Inc. primarily develops and provides its medical devices in the United States and is headquartered in Minneapolis, Minnesota.

Tactile Systems Technology's brand reputation over the past year appears positive, driven by strong financial performance and strategic initiatives. The company reported strong Q3 2025 earnings and full-year 2025 revenue growth. Strategic growth initiatives include the acquisition of Lymphotec and investments in a new CRM system. Favorable Medicare policy changes have been a positive development. Tactile Systems Technology has received a consensus rating of "Moderate Buy" from analysts. A new Medicare prior authorization requirement is a potential short-term headwind.

Tactile Systems Technology, Inc. has a mixed ownership structure. Approximately 71.16% of the company's stock is owned by institutional investors, with major holders including BlackRock, Inc. and Vanguard Group Inc. Insiders hold about 3.37% of the company's stock, and they have sold more stock than they have bought in the past three months. Public companies and individual investors own approximately 25.46% of the stock.